First-line therapy in ovarian cancer trials

Tate Thigpen, Andreas DuBois, Jessica McAlpine, Philip DiSaia, Keiichi Fujiwara, William Hoskins, Gunnar Kristensen, Robert Mannel, Maurie Markman, Jacobus Pfisterer, Michael Quinn, Nick Reed, Ann MarieSwart, Jonathan Berek, Nicoletta Colombo, Gilles Freyer, Dolores Gallardo, Marie Plante, Andres Poveda, Lawrence RubinsteinMonica Bacon, Henry Kitchener, Gavin C E Stuart

    Research output: Contribution to journalArticlepeer-review


    At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients. A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)? A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials? A3: Is the 2004 GCIG-recommended standard comparator arm still valid? A4: What is the role of modifying dose, schedule, and delivery of chemotherapy? A5: What role does surgery play today? Copyright © 2011 by IGCS and ESGO.
    Original languageEnglish
    Pages (from-to)756-762
    Number of pages6
    JournalInternational Journal of Gynecological Cancer
    Issue number4
    Publication statusPublished - May 2011


    • Clinical trials
    • First line therapy
    • Ovarian cancer


    Dive into the research topics of 'First-line therapy in ovarian cancer trials'. Together they form a unique fingerprint.

    Cite this